SRI’s SynFini platform combines Al and automation to speed small-molecule drug discovery
Biomedical R&D services
Formulating a solution to mass radiation exposure
XDR weld visualization technology gives welders full 3D view of workspace, as smart helmet collects data to help train new technicians.
Accurately identifying and predicting synthetic lethal partnerships, to combat cancerous cells
An AI-guided precision cancer therapy platform
Automating chemical drug discovery and synthesis
SRI International’s continuous flow SynFini™ Suite produced multiple nucleoside antivirals in a single day.
Intracellular delivery—now a reality for many types of therapeutics
Unlocking the therapeutic potential of antisense oglionucleotides and other biologics.
Partnering to Rapidly Advance ZMappTM for Ebola Treatment
SRI scientists partner with Mapp Biopharmaceutical to accelerate FDA approval for clinical trials.
HOPO: Partnering to Advance Therapy for Radiation Exposure
SRI scientists collaborate with Lawrence Berkeley National Laboratory to chart a path for obtaining regulatory approval for a clinical development plan for a novel decorporation agent.
Rising to the COVID-19 challenge: using preclinical models to assess vaccines and antivirals, upcoming webinar hosted by Xtalks
SRI, as one of NIH’s leading preclinical partners, has a long history of rapid response to critical issues like COVID-19.
February 2021 – Immunology at SRI
SRI scientists and taming and leveraging the immune system to protect human health